Acute coronary syndrome (ACS) is one of the leading
causes of death in
cardiovascular disease.
Percutaneous coronary intervention (PCI) is an important
method for the
treatment of
coronary heart disease (CHD), and it has greatly reduced the
mortality of ACS
patients since its application. However, a series of new problems may occur after PCI, such as in-
stent restenosis,
no-reflow phenomenon, in-
stent neoatherosclerosis, late
stent thrombosis,
myocardial ischemia-
reperfusion injury, and malignant ventricular arrhythmias, which result in the occurrence of
major adverse cardiac events (
MACE) that seriously reduce the postoperative benefit for
patients. The inflammatory response is a key mechanism of
MACE after PCI. Therefore, examining effective anti-inflammatory
therapies after PCI in
patients with ACS is a current
research focus to reduce the
incidence of
MACE. The pharmacological mechanism and
clinical efficacy of routine Western
medicine treatment for the anti-inflammatory
treatment of CHD have been verified. Many
Chinese medicine (CM) preparations have been widely used in the
treatment of CHD. Basic and clinical studies showed that
effectiveness of the combination of CM and Western
medicine treatments in reducing
incidence of
MACE after PCI was better than Western
medicine treatment alone. The current
paper reviewed the potential mechanism of the inflammatory response and occurrence of
MACE after PCI in
patients with ACS and the
research progress of combined
Chinese and Western
medicine treatments in reducing
incidence of
MACE. The results provide a theoretical basis for further
research and clinical
treatment.